PTGS2 and non-small cell lung carcinoma: In a phase III study, CALGB 30801, the enrolled patients were selected based on COX-2 expression assessed using immunohistochemistry, and the COX-2 inhibitor celecoxib failed to improve prognosis in NSCLC with high COX-2 expression.